Can-Fite BioPharma (CANF) announced that it has entered into definitive agreements for the purchase and sale of 2.5M of the company’s American Depositary Shares at a purchase price of $1.20 per ADS, in a registered direct offering. H.C. Wainwright is acting as the exclusive placement agent for the offering. The gross proceeds from the, before deducting the placement agent’s fees and other offering expenses payable by the company, are expected to be $3.0M. Can-Fite intends to use the net proceeds for funding research and development and clinical trials and for other working capital and general corporate purposes.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CANF:
- Can-Fite BioPharma trading halted, news pending
- Can-Fite Projects $685M Revenue from Partnerships
- Can-Fite BioPharma announces completion of analysis of current partnerships
- Can-Fite BioPharma Reports 2024 Financial Results and Clinical Advances
- Can-Fite BioPharma reports FY24 EPS 0c vs 1c last year